Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 201–300 of 1,000
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 107
How can we cure a heart “in flame”? A translational view on inflammation in heart failure
Hofmann, U., & Frantz, S. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0356-y · Cited by 118
Nochioka, K., Sakata, Y., TAKAHASHI, J. C., Miyata, S., Miura, M., Takada, T., Fukumoto, Y., Shiba, N., Shimokawa, H., & for the CHART-2 Investigators (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0127 · Cited by 119
Vivo, R. P., Krim, S. R., Çevik, C., & Witteles, R. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.037 · Cited by 109
Jafri, H., Alsheikh-Ali, A. A., & Karas, R. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-12-201012210-00006 · Cited by 106
Inflammatory Biomarkers in Heart Failure Revisited: Much More than Innocent Bystanders
von Haehling, S., Schefold, J. C., Lainščak, M., Doehner, W., & Anker, S. D. (2009) · Heart Failure Clinics · doi:10.1016/j.hfc.2009.04.001 · Cited by 112
Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials
Gregson, J., Sharples, L. D., Stone, G. W., Burman, C., Öhrn, F., & Pocock, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1034 · Cited by 115
Hermida, N., & Balligand, J. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5537 · Cited by 125
Calcium and Reactive Oxygen Species Signaling Interplays in Cardiac Physiology and Pathologies
Nicolo, B. D., Cataldi-Stagetti, E., Diquigiovanni, C., & Bonora, E. (2023) · Antioxidants · doi:10.3390/antiox12020353 · Cited by 117
Autophagy: an affair of the heart
Gottlieb, R. A., & Mentzer, R. M. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9367-2 · Cited by 103
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis
Cleland, J. G. F., Carubelli, V., Castiello, T., Yassin, A., Pellicori, P., & Antony, R. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9306-2 · Cited by 111
Self-citationPentraxin-3 in Chronic Heart Failure: The CORONA and GISSI-HF Trials
Latini, R., Gullestad, L. L., Masson, S., Nymo, S. H., Ueland, T., Cuccovillo, I., Vårdal, M., Bottazzi, B., Mantovani, A., Lucci, D., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs092 · Cited by 102
Self-citationEffects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial
Maggioni, A. P., Fabbri, G., Lucci, D., Marchioli, R., Franzosi, M. G., Latini, R., Nicolosi, G. L., Porcu, M., Cosmi, F., Stefanelli, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp357 · Cited by 100
Kostapanos, M. S., Milionis, H. J., & Elisaf, M. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/13168600-000000000-00000 · Cited by 113
Lipinski, M. J., Cauthen, C. A., Biondi‐Zoccai, G., Abbate, A., Vrtovec, B., Khan, B. V., & Vetrovec, G. W. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.055 · Cited by 100
Cambou, J., Aboyans, V., Constans, J., Lacroix, P., Dentans, C., & Bura-Rivière, A. (2010) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2010.02.009 · Cited by 98
Glutamate synthase: a fascinating pathway from L-glutamine to L-glutamate
van den Heuvel, R. H. H., Curti, B., Vanoni, M. A., & Mattevi, A. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3316-0 · Cited by 101
Rosuvastatin: Beyond the cholesterol-lowering effect
Cortese, F., Gesualdo, M., Cortese, A. M., Carbonara, S., Devito, F., Zito, A., Ricci, G., Scicchitano, P., & Ciccone, M. M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.012 · Cited by 108
Rahimi, K., Bhala, N., Kamphuisen, P., Emberson, J., Biere-Rafi, S., Krane, V., Robertson, M., Wikstrand, J., & McMurray, J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001310 · Cited by 94
Self-citationNymo, S. H., Hulthe, J., Ueland, T., McMurray, J. J. V., Wikstrand, J., Askevold, E. T., Yndestad, A., Gullestad, L. L., & Aukrust, P. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft125 · Cited by 107
Self-citationGullestad, L. L., Ueland, T., KJEKSHUS, J. K., Nymo, S. H., Hulthe, J., Muntendam, P., McMurray, J. J. V., Wikstrand, J., & Aukrust, P. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.08.021 · Cited by 102
Self-citationCharacterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI
Giustino, G., Mehran, R., Dangas, G., Kirtane, A. J., Redfors, B., Généreux, P., Brener, S. J., Prats, J., Pocock, S., Deliargyris, E., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.018 · Cited by 100
Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
Lee, M. M. Y., Sattar, N. A., McMurray, J. J. V., & Packard, C. J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0800-z · Cited by 100
Self-citationColeman, C. I., Reinhart, K., Kluger, J., & Michael White, C. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x292029 · Cited by 90
Howlett, J. G., McKelvie, R. S., Arnold, J. M. O., Costigan, J., Dorian, P., Ducharme, A., Estrella-Holder, E., Ezekowitz, J. A., Giannetti, N., Haddad, H. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70477-5 · Cited by 100
Curran, F. M., Bhalraam, U., Mohan, M., Singh, J. S., Anker, S. D., Dickstein, K., Doney, A. S. F., Filippatos, G. S., Casella, G., Metra, M., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13424 · Cited by 101
Update on statin-mediated anti-inflammatory activities in atherosclerosis
Montecucco, F., & Mach, F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0150-y · Cited by 99
Self-citationKristensen, S. L., Køber, L., Jhund, P. S., Solomon, S. D., Kjekshus, J., McKelvie, R. S., Zile, M. R., Granger, C. B., Wikstrand, J., Komajda, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012284 · Cited by 88
Self-citationKorhonen, M. J., Robinson, J. G., Annis, I. E., Hickson, R. P., Bell, J. S., Hartikainen, J., & Fang, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.783 · Cited by 90
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
Lip, G. Y. H., Ponikowski, P. P., Andreotti, F., Anker, S. D., Filippatos, G., Homma, S., Morais, J., Pullicino, P. M., Rasmussen, L. H., Marín, F. R., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs073 · Cited by 97
Self-citationPoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86
“As opposed to individuals without heart failure, low cholesterol concentrations in patients suffering from heart failure are associated with a worse prognosis [122, 123].”
BackgroundCoenzyme Q10: is there a clinical role and a case for measurement?
Molyneux, S. L., Young, J. M., Florkowski, C. M., Lever, M., & George, P. M. (2008) · PubMed · Cited by 125
Oesterle, A., & Liao, J. K. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180817155058 · Cited by 92
“Both large randomized control trials that have been conducted in heart failure, GISSI-HF and CORONA, did not show any mortality benefit [57, 58].”
BackgroundSeifinoferest, B., Tanbakouchian, A., Larijani, B. A., & Mahdavi, M. R. (2021) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202100072 · Cited by 87
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure
Dietl, A., & Maack, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0347-7 · Cited by 90
Clinical utility of antigen carbohydrate 125 in heart failure
Núñez, J. E., Miñana, G., Núñez, E., Chorro, F. J., Bodí, V., & Sanchís, J. M. (2013) · Heart Failure Reviews · doi:10.1007/s10741-013-9402-y · Cited by 95
Muscle- and skeletal-related side-effects of statins: tip of the iceberg?
Auer, J., Sinzinger, H. F., Franklin, B., & Berent, R. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314550804 · Cited by 94
High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial
Kalogeropoulos, A. P., Tang, W. H. W., Hsu, A., Felker, G. M., Hernandez, A. F., Troughton, R. W., Voors, A. A., Anker, S. D., Metra, M., McMurray, J. J. V., et al. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.02.002 · Cited by 89
Self-citationExtreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1178-6 · Cited by 127
Ghio, S., Scelsi, L., Latini, R., Masson, S., Eleuteri, E., Palvarini, M., Vriz, O., Pasotti, M., Gorini, M., Marchioli, R., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq172 · Cited by 82
Tuñón, J., Blanco‐Colio, L. M., Cristóbal, C., Tarín, N., Higueras, J., Huelmos, A. I., Alonso, J. J., Egido, J., Asensio, D., Lorenzo, Ó., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.10.012 · Cited by 81
Making Sense of Statistics in Clinical Trial Reports
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.014 · Cited by 86
Self-citationMedical therapy for chronic heart failure
Krum, H., & Teerlink, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61038-6 · Cited by 86
An Overview of the Extra-Lipid Effects of Rosuvastatin
Kostapanos, M. S., Milionis, H. J., & Elisaf, M. (2008) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248408318628 · Cited by 78
“Significant reductions in patient hospitalizations were observed, along with reductions in LDL-C and CRP with rosuvastatin versus placebo.(91)”
BackgroundErbs, S., Beck, E. B., Linke, A., Adams, V., Gielen, S., Kränkel, N., Möbius‐Winkler, S., Höllriegel, R., Thiele, H., Hambrecht, R., et al. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.02.019 · Cited by 79
Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure
Horwich, T. B., Hernandez, A. F., Dai, D. W. H., Yancy, C. W., & Fonarow, G. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.004 · Cited by 84
Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
Strandberg, T. E. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0793-7 · Cited by 77
A Contemporary View on Endothelial Function in Heart Failure
Shantsila, E., Wrigley, B. J., Blann, A. D., Gill, P. S., & Lip, G. Y. H. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs066 · Cited by 77
Stramba‐Badiale, M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq094 · Cited by 87
Benefits of statin therapy and compliance in high risk cardiovascular patients
Deedwania, P., & Lardizabal (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s9474 · Cited by 78
Apostolakis, S. Z., Lip, G. Y. H., & Shantsila, E. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp327 · Cited by 80
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 80
Inzucchi, S. E., Docherty, K. F., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., Solomon, S. D., Verma, S., Bělohlávek, J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1675 · Cited by 80
Self-citationHow robust are clinical trials in heart failure?
Docherty, K. F., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw427 · Cited by 83
Self-citationWebber, M. R., Jackson, S. P., Moon, J., & Captur, G. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00199-y · Cited by 87
Statins and the autonomic nervous system
Millar, P. J., & Floras, J. S. (2013) · Clinical Science · doi:10.1042/cs20130332 · Cited by 78
Aging, telomeres and heart failure
Wong, L. S. M., van der Harst, P., de Boer, R. A., Huzen, J., van Gilst, W. H., & van Veldhuisen, D. J. (2010) · Heart Failure Reviews · doi:10.1007/s10741-010-9173-7 · Cited by 75
Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
Pedersen, T. R. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/1158822-s0-000000000-00000 · Cited by 74
van den Hoek, H. L., Bos, W. J. W., de Boer, A., & van de Garde, E. M. W. (2011) · BMJ · doi:10.1136/bmj.d7281 · Cited by 78
Ponikowski, P. P., Andreotti, F., Anker, S. D., Filippatos, G., Homma, S., Morais, J., Pullicino, P. M., Rasmussen, L., Marín, F. R., Lane, D. A., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0578 · Cited by 74
Self-citationAssessing the Role of Rare Genetic Variation in Patients With Heart Failure
Povysil, G., Chazara, O., Carss, K. J., Deevi, S. V. V., Wang, Q., Armisen, J., Paul, D. S., Granger, C. B., Kjekshus, J., Aggarwal, V., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6500 · Cited by 73
Self-citationGeographic Differences in Heart Failure Trials
Ferreira, J. P., Girerd, N., Rossignol, P., & Zannad, F. M. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.326 · Cited by 77
Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure
Metra, M., Zacà, V., Parati, G., Agostoni, P., Bonadies, M., Ciccone, M. M., Dei, A., Iacoviello, M., Lagioia, R., Lombardi, C., et al. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32834058d1 · Cited by 80
The cardiopulmonary continuum systemic inflammation as ‘common soil’ of heart and lung disease
Ukena, C., Mahfoud, F., Kindermann, M., Kindermann, I., Bals, R., Voors, A. A., van Veldhuisen, D. J., & Böhm, M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.04.082 · Cited by 85
Self-citationLDL cholesterol in CKD—to treat or not to treat?
Massy, Z. A., & de Zeeuw, D. (2013) · Kidney International · doi:10.1038/ki.2013.181 · Cited by 78
Vascular Calcification and Renal Bone Disorders
Lu, K., Wu, C., Yen, J.-F., & Liu, W.-C. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/637065 · Cited by 81
Lainščak, M., von Haehling, S., & Anker, S. D. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.149 · Cited by 76
Diabetic cardiomyopathy – a distinct disease?
Khavandi, K., Khavandi, A., Asghar, O., Greenstein, A. S., Withers, S., Heagerty, A. M., & Malik, R. A. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.016 · Cited by 81
Castro, P., Miranda, R., Verdejo, H., Greig, D. P., Gabrielli, L., Alcaíno, H., Chiong, M., Bustos, C., García, L., Mellado, R., et al. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.01.012 · Cited by 76
Khan, S. U., Rahman, H., Okunrintemi, V., Riaz, H., Khan, M. S., Sattur, S., Kaluski, E., Lincoff, A. M., Martin, S. S., & Blaha, M. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011581 · Cited by 70
Pleiotropic Effects and Cholesterol-Lowering Therapy
Shaw, S. M., Fildes, J. E., Yonan, N. A., & Williams, S. G. (2008) · Cardiology · doi:10.1159/000137692 · Cited by 72
“both compounds lowered plasma thrombin-anti-thrombin complexes. Simvastatin also reduced P-selectin (a cell adhesion molecule found on activated platelets). Ongoing interest in the pleiotropic effects of statins has extended to their assessment in congestive heart failure. This condition, which possesses well-recogniz…”
ResultStructure and function of coagulogen, a clottable protein in horseshoe crabs
Osaki, T., & Kawabata, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3396-5 · Cited by 69
Tousoulis, D., Andreou, I., Tsiatas, M. L., Miliou, A., Tentolouris, C. A., Siasos, G., Παπαγεωργίου, Ν., PAPADIMITRIOU, C. A., Dimopoulos, M. A., & Stefanadis, C. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.11.002 · Cited by 70
Gravning, J. A., Askevold, E. T., Nymo, S. H., Ueland, T., Wikstrand, J., McMurray, J. J. V., Aukrust, P., Gullestad, L. L., & KJEKSHUS, J. K. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000450 · Cited by 69
Self-citationFatigue as a Predictor of Outcome in Patients With Heart Failure
Moreno, A. C. P., Jhund, P. S., MacDonald, M. R., Petrie, M. C., Cleland, J. G. F., Böhm, M., van Veldhuisen, D. J., Gullestad, L. L., Wikstrand, J., KJEKSHUS, J. K., et al. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.01.001 · Cited by 74
Self-citationPons, F., Lupón, J., Urrútia, A., González, B., Crespo, E., Díez, C., Cano, L., Cabanes, R., Altimir, S., Coll, R., et al. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70089-0 · Cited by 68
New Concepts in Sudden Cardiac Arrest to Address an Intractable Epidemic
Narayan, S. M., Wang, P. J., & Daubert, J. P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.083 · Cited by 82
Statin therapy in the elderly: A review
Szadkowska, I., Stańczyk, A., Aronow, W. S., Kowalski, J., Pawlicki, L., Ahmed, A., & Banach, M. (2009) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2008.12.012 · Cited by 69
“Statin therapy in the elderly: A review Iwona Szadkowska a,*, Adam Stanczyk b, Wilbert S. Aronow c, Jan Kowalski a, Lucjan Pawlicki a, Ali Ahmed d, Maciej Banach e a Department of Internal Diseases and Cardiological Rehabilitation, Medical University of Lodz, Hallera Sq. 1, 90-647 Lodz, Poland b Ward of Noninvasive Ca…”
BackgroundInfluentialKhan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Alberton, M., Wu, P., Druyts, E., Briel, M., & Mills, E. J. (2012) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcr158 · Cited by 66
By Jove! What Is a Clinician to Make of JUPITER?
Kaul, S., Morrissey, R. P., & Diamond, G. A. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.189 · Cited by 68
Deo, S. H., Fisher, J. P., Vianna, L. C., Kim, A., Chockalingam, A., Zimmerman, M. C., Zucker, I. H., & Fadel, P. J. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00289.2012 · Cited by 70
Ibrahim, N. E., Song, Y., Cannon, C. P., Doros, G. D., Russo, P. A., Ponirakis, A., Alexanian, C. C., & Januzzi, J. L. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12455 · Cited by 76
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 80
Self-citationNochioka, K., Sakata, Y., Miyata, S., Miura, M., Takada, T., Tadaki, S., Ushigome, R., Yamauchi, T., Takahashi, J., Shimokawa, H., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-0865 · Cited by 65
Nymo, S., Ueland, T., Askevold, E. T., Flo, T., Kjekshus, J., Hulthe, J., Wikstrand, J., Mcmurray, J., van Veldhuisen, D., Gullestad, L., et al. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02503.x · Cited by 60
Self-citationPredictors of short term mortality in heart failure — Insights from the Euro Heart Failure survey
Velavan, P., Khan, N. K., Goode, K. M., Rigby, A. S., Loh, P. H., Michel Komajda, N., Folláth, F., Swedberg, K. B., Madeira, H. C., & Cleland, J. G. F. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.08.004 · Cited by 65
“But, the recently published CORONA study did not support this hypothesis in ischaemic heart failure [21] and another major trial examining this hypothesis in both ischaemic and nonischaemic heart failure (GISSI-HF) will be reported soon.”
ResultSelf-citationThe (pro)renin receptor in health and disease
Nguyen, G. (2010) · Annals of Medicine · doi:10.3109/07853890903321567 · Cited by 65
Desai, A. S., Claggett, B. L., Pfeffer, M. A., Bello, N. A., Finn, P. V., Granger, C. B., McMurray, J. J. V., Pocock, S., Swedberg, K. B., Yusuf, S., et al. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001567 · Cited by 69
Self-citationPacker, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 70
McKelvie, R. S., Michel Komajda, N., McMurray, J. J. V., Zile, M. R., Ptaszynska, A., Donovan, M., Carson, P. E., & Massie, B. M. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.09.007 · Cited by 64
Self-citationOsteoprotegerin Predicts Progression of Chronic Heart Failure: Results From CORONA
Ueland, T., Dahl, C. P., KJEKSHUS, J. K., Hulthe, J., Böhm, M., Mach, F., Goudev, A., Lindberg, M., Wikstrand, J., Aukrust, P., et al. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.957332 · Cited by 64
“0001 Non-CV mortality 75 (5) 15 (3) 16 (3) 44 (9) 0.”
Self-citationKristensen, M. E. L., Christensen, P. M., & Hallas, J. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-007118 · Cited by 67
Meta-Analysis of the Effect of Statins on Mortality in Patients With Preserved Ejection Fraction
Liu, G., Zheng, X., Xu, Y.-L., Ru, J., Hui, R., & Huang, X. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.12.023 · Cited by 67
Wang, S., Cai, R., Yuan, Y., Varghese, Z., Moorhead, J. F., & Ruan, X. Z. (2017) · Scientific Reports · doi:10.1038/srep39982 · Cited by 79
Rosuvastatin in Older Patients with Systolic Heart Failure
Florkowski, C. M., Molyneux, S. L., & George, P. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmc073536 · Cited by 63
Scirica, B. M., Cannon, C. P., Sabatine, M. S., Jarolím, P., Sloane, S., Rifai, N., Braunwald, E., Morrow, D. A., & for the PROVE IT–TIMI 22 Investigators (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.117192 · Cited by 70
Tsai, C., Wu, C., Lee, J.-K., Chang, S., Kuo, Y., Wang, Y., Lai, L., Chiang, F., Hwang, J., & Lin, J.-L. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv008 · Cited by 62
Perera, R., McFadden, E., McLellan, J., Lung, T., Clarke, P., Pérez, T., Fanshawe, T., Dalton, A., Farmer, A., Glasziou, P., et al. (2015) · Health Technology Assessment · doi:10.3310/hta191000 · Cited by 62
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.